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In Crohn’s disease (CD) two third of patients have a clinical response to anti-
TNF, but less than 50% of the patients who respond to therapy maintain the 
response one year after the beginning of the anti-TNF therapy.  
Part of the inability to maintain long-term remission is thought to result from 
the occurrence of antibody against adalimumab (AAA) and most of this loss of 
efficacy may be due to an inadequate optimization of the therapeutic dosage [1].  
In case of relapse, an empiric adalimumab dosage increment in a patient with a high 
level of AAA or with adalimumab trough level in therapeutic range is unlikely useful 
and may expose the patient to damage resulting from over-therapeutic dose of the 
drug or to AAA-mediated adverse events. Identifying patients with subtherapeutic 
adalimumab trough levels allows to target the therapy to those patients who really 
need a different administration rate. 
      Till now there are no studies that prove the ability of trough adalimumab level 
and of AAA to predict the long-term disease behaviour in CD patients naïve to anti-
TNF. 
We conducted a double blind (adalimumab trough levels and AAA had been 
available to the clinicians at the end of the study; the laboratory was blind to patient’s 
clinical characteristics) prospective, monocenter, observational study in the “Città 
della Salute e della Scienza” hospital in Turin, Italy, between January 2016 and April 
2017. 
Inclusion criteria were age higher than 14 years old, CD diagnosed according 
to ECCO criteria [2], primary response to the adalimumab induction regimen, 
treatment with adalimumab (indication luminal CD) from at least 2 months, in a 
stable dose of 40 mg every two week, naïve to other anti-TNF or adalimumab. The 
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follow-up was concluded in case of a change in the dose or stop of adalimumab due 
to loss of efficacy, adverse drug reaction, complete response and in case of the need 
to start systemic corticosteroids. 
The adalimumab trough levels and the AAA were randomly assessed, one time 
only per patient, the day before a next administration of the drug, together with C-
reactive protein (CRP) and fecal calprotectin. At the end of follow up the AAA trough 
levels and the CRP were again assessed. Clinical activity was assessed with 
Harvey-Bradshaw index [3].  
  The method used was the TNFα-Blocker ELISA kit (Immundiagnostik). For 
adalimumab trough levels dosing the Immundiagnostik TNFα-Blocker monitoring, 
adalimumab drug level ELISA (K9657) has been used. For the AAA dosage, the 
Immundiagnostik TNFα-Blocker ADA, TOTAL antibodies against adalimumab ELISA 
(K9651) has been used. These kits allow the measurement of the AAA even if the 
adalimumab is present in the patient serum.  
The primary outcomes were 1) the adalimumab random trough level predictive 
ability of disease activity and of CRP level at the end of follow up, calculating the 
ROC curve with the optimum sensitivity and specificity value; 2) the AAA random 
trough level predictive ability of disease activity and of CRP at the end of follow up; 
3) the adalimumab random trough level predictive ability of the AAA onset at the end 
of follow up.  
The secondary outcomes were 1) the association between the adalimumab 
random trough level and the disease activity, CRP, fecal calprotectin in that moment; 
2) the association between the AAA random trough level and the disease activity, 
CRP, fecal calprotectin in that moment; 3) the influence of azathioprine combination 
therapy on the adalimumab and the AAA trough levels. 
5 
 
The statistical significance level was set to 95%. The statistical analysis was 
performed by using MedCalc software (version 14.8.1). 
In the study period 40 CD currently treated with adalimumab, naïve to other anti-
TNF, patients were included. The clinical characteristics of included patients are 
reported in Table 1. 
 
Table 1 
 
The average follow-up was 10 months (range 3 – 14 months).  
At the time of the assessment, 28 of 40 (70%) patients were in remission or in 
mild disease activity (HBI <= 7), 12 of 35 (30%) were in moderate or severe disease 
activity (HBI >= 8). 
No adverse reaction to adalimumab administration occurred.  
An adalimumab trough level > 0.65 [µg/ml] predicted remission / mild disease 
activity (HBI <= 7) 10 months after the dosage with an AUC = 0.85 (P < 0.0001) 
(sensitivity = 80%, specificity = 90%) (Figure 1). 
 
Figure 1 
 
An adalimumab trough level > 1.8 [µg/ml] predicted a negative CRP 10 
months after the adalimumab trough level dosage with an AUC = 0.85 (P < 0.0001) 
(sensitivity = 85.7%, specificity = 78.3%). 
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An AAA trough level <= 0.1 [AU/ml] predicted remission / mild disease activity 
10 months after the dosage with an AUC = 0.82 (P = 0.0001) (sensitivity = 80%, 
specificity = 85.7%) (Figure 2). 
 
Figure 2 
 
An AAA trough level <= 1.1 [AU/ml] predicted a negative CRP 10 month after 
the AAA trough level dosage with an AUC = 0.84 (P = 0.0002) (sensitivity = 85.7%, 
specificity = 82.6%). 
14 of 40 patients (35%) have developed an AAA trough level > 0.1 [AU/ml], at 
a median time of 13 months from the beginning of adalimumab therapy. 
In all patients that developed an AAA trough level > 0.1 [AU/ml], the 
adalimumab trough level had fallen under the threshold of 1.9 [µg/ml]; no patients 
that maintained the adalimumab trough level over this threshold had developed AAA 
at the end of follow up 
The increasing of time in adalimumab therapy did not correlate with the 
development of anti-adalimumab antibody (P = 0.75). 
In patients with a CD in remission or mild disease activity (HBI <= 7) at the 
time of the random dosage, the median adalimumab trough level resulted 9.4 
[µg/ml], versus a median adalimumab trough level of 0.5 [µg/ml] in patients with a 
CD in moderate or severe disease activity (HBI >= 8) (P = 0.0007) 
A declining of adalimumab trough level correlated with higher level, at that 
time, of CRP (correlation coefficient = -0.64, P = 0.0002, 95% C.I. = -0.81 - -0.35) 
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and of calprotectin (correlation coefficient = -0.64, P = 0.0002, 95% C.I. = -0.65 - -
0.26).    
In patients with a CD in remission or mild disease activity (HBI <= 7) at the 
time of the random dosage, the median AAA trough level resulted 0.1 [AU/ml], 
versus a median AAA trough level of 5 [AU/ml] in patients with a CD in moderate or 
severe disease activity (P = 0.002)  
An increasing of AAA trough level correlated with higher level, at that time, of 
CRP (correlation coefficient = 0.8, P < 0.0001, I.C. 95% = 0.61 – 0.9) and of 
calprotectin (correlation coefficient = 0.7, P = <0.0001, I.C. 95% = 0.45 – 0.85). 
The adalimumab – azathioprine combination therapy did not change the 
adalimumab median trough levels at the time of the random dosage (8 [µg/ml] in 
monotherapy group, 4.5 [µg/ml] in combination therapy group, P = 0.47).  
The adalimumab – azathioprine combination therapy did not change the AAA 
median trough levels at the time of the random dosage (0.1 [AU/ml] in monotherapy 
group, 2.6 [AU/ml] in combination therapy group, P = 0.31).  
By comparing our findings with those of the literature, in a multicentre, 
retrospective, cohort study an adalimumab threshold trough level of 3 [µg/ml] best 
differs the presence of absence of inflammation in that moment [4]. In a retrospective 
study on 30 CD patients experience to infliximab, the presence of AAA was related 
with a primary failure to adalimumab [5]. In an observational, prospective, 
monocenter study about 168 CD patients with a secondary failure to infliximab, the 
patients with AAA at the end of follow up had a lower adalimumab trough level at 4 
weeks of therapy [6]. A combination therapy with azathioprine did not change the 
therapeutic results. In a monocenter study about 40 CD patients treated with 
adalimumab maintenance therapy, the adalimumab trough levels were significantly 
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elevated in patients with inactive disease compared to those with active disease. A 
combination therapy with azathioprine did not change the adalimumab trough level 
[7]. In a transversal, multicentre study about 71 CD patients at ROC curve resulted a 
positive correlation between adalimumab trough level and the remission in that 
moment. There wasn’t correlation between adalimumab trough level and a 
combination therapy with azathioprine. The AAA level did not differentiate an active 
disease [8]. In a prospective, observational cohort study about 23 CD patients, the 
patients with a disease in remission had higher trough adalimumab level respect to 
patients with a mild activity of disease and to patients with moderate or severe 
activity of disease. The median adalimumab trough level resulted statistically lower in 
patients with AAA than in patients without [9]. In a retrospective cross-sectional study 
of 67 with IBD treated with adalimumab the authors [10] found a median serum 
levels of adalimumab significantly higher in patients with mucosal healing than in 
patients with active disease. 
Our is the first double blind, prospective study in CD patients treated with 
adalimumab, naive to other anti-TNF that demonstrates the ability of a random 
adalimumab and AAA trough level to predict a well-controlled disease at almost one 
year from the dosage.  
Consistent with the clinical disease activity, the fact that a statistically 
significant negative correlation was found between the adalimumab trough levels 
and the CRP and the calprotectin at the time of the biological drug dosing, shows 
that a low serum drug level is insufficient to control the inflammation. 
In agreement with all the studies reported in literature, there is not a 
statistically significant difference between the adalimumab median trough levels or 
the AAA median trough levels in patients in combination therapy with azathioprine. 
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Further investigation in a large cohort and a correlation with the mucosal 
healing would be of benefit. 
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Figure 1. ROC curve analysis: adalimumab trough levels – disease activity at the 
end of follow up 
Figure 2. ROC curve analysis: AAA trough levels – disease activity at the end of 
follow up 
 
 
 
 
 
 
